Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Clinical Trial of Berubicin for the Treatment of Glioblastoma (GBM)

Trial Profile

A Phase IIa Clinical Trial of Berubicin for the Treatment of Glioblastoma (GBM)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berubicin (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors CNS Pharmaceuticals
  • Most Recent Events

    • 21 Nov 2019 According to a CNS Pharmaceuticals media release, In its request, the Company outlined its rationale for the continued investigation of the compound and detailed key questions for the FDA, including its permission to utilize the supply of Berubicin acquired from Reata Pharmaceuticals Inc. in the planned upcoming Phase II clinical trial. The company has performed a preliminary purity testing and analysis on Reata's supply of Berubicin and verified that it is 99.9% pure.
    • 21 Nov 2019 According to a CNS Pharmaceuticals media release, company filed a Pre-IND meeting request for Berubicin for IV for the Treatment of Glioblastoma Multiforme to the US Food and Drug Administration.
    • 25 Apr 2018 As per CNS Pharmaceuticals website, the company expects to commence this phase 2a trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top